Is HRT Safe Now? What the FDA Label Change Means

Updated August 2026

For more than twenty years, the strongest warning the FDA can place on a medication sat on every estrogen product for menopause. Most women never read the label itself. They absorbed it anyway: through a doctor's hesitation, a mother's story, a quiet sense that hormones were dangerous.

That warning was written for a different era, based on a study of women very different from the ones asking about hormone replacement therapy (HRT) today. In November 2025, the FDA acknowledged this and took the warning off.

This is good news. It is also nuanced news, and the nuance is worth a few minutes of your time.

The FDA's 2025 HRT label change removed the black box warning about breast cancer, cardiovascular risk, and probable dementia from hormone replacement therapy products, replacing a 2002-era caution with more current, individualized guidance. Source: FDA press announcement, November 10, 2025

Key takeaways

• On November 10, 2025, the FDA announced the removal of boxed warnings from HRT products, including low-dose vaginal estrogen. New labels include age-specific guidance.
• The warning traced back to the 2002 Women's Health Initiative study, whose participants averaged 63 years old: more than a decade past the typical start of menopause at 51.
• The change does not mean HRT is right for everyone. Risk still depends on your age, how close you are to the transition, and your personal health history. It remains a decision to make with your doctor.
• Hormones are one lever, not the whole system. In Project M's 35-woman consumer research study, women on HRT still reported brain fog, tension, and 3am wakings at nearly the same levels as women not on it. Many women use hormonal and herbal support together.

What the black box warning said, and where it came from

The boxed warning, added to estrogen products starting in 2003, cautioned that hormone therapy could raise the risk of breast cancer, stroke, cardiovascular events, and probable dementia. It also told doctors to prescribe the lowest dose for the shortest possible time. Source: Contemporary OB/GYN

The warning came from the Women's Health Initiative (WHI), a large federal study launched in 1991. In 2002, one arm of the trial was stopped early after researchers saw safety signals in women taking estrogen plus progestin. The headlines were alarming, and the effect was immediate. Use of hormone therapy among postmenopausal women fell from roughly 27% to 5% between 1999 and 2020. Source: Harvard Health Publishing

Two details got lost in those headlines. The roughly 16,000 women in the halted trial had a mean age of 63, well past the age when most women would actually start HRT. And the hormone formulations studied are not the ones most commonly prescribed today. Modern options include lower doses and skin patches that carry a different risk profile. Sources: Contemporary OB/GYN, Harvard Health Publishing

In short, a warning built on data from women in their 60s and 70s shaped the choices of women in their 40s and 50s for two decades.

What changed in November 2025

The FDA directed manufacturers to remove the boxed warnings about cardiovascular risk, breast cancer, and probable dementia from HRT products, both systemic and low-dose vaginal estrogen. The decision followed a scientific literature review, an expert panel in July 2025, and a public comment period. Source: FDA press announcement

The FDA pointed to research suggesting that women who start HRT within 10 years of menopause onset, generally before age 60, may see meaningful benefits, including lower cardiovascular and fracture risk. New labels are expected to carry age-specific guidance reflecting this. FDA Commissioner Marty Makary framed it plainly: "Women and their physicians should make decisions based on data, not fear." Sources: FDA press announcement, Harvard Health Publishing

Medical societies largely welcomed the move, with caveats. The Menopause Society supported removing the warning from low-dose vaginal estrogen, which delivers only trace amounts to the bloodstream, while noting that systemic estrogen still carries risks that deserve a detailed conversation. Their summary: "The risks are low for younger, healthy women initiating hormone therapy closer to the menopause transition." Source: The Menopause Society

What this means for you, and what it does not

The label change means the conversation about HRT can finally start from evidence instead of a 2002 headline. It does not mean HRT is now recommended for every woman, or that all risk has vanished.

A few things are still true:

• Timing matters. The benefit-risk picture looks best for women who start within about 10 years of their final period, and less favorable for those who start much later. Source: Contemporary OB/GYN
• History matters. Doctors still generally advise against systemic HRT for women with a history of breast cancer, blood clots, stroke, heart attack, or certain hormone-sensitive cancers. Source: Harvard Health Publishing
• One warning stays. Systemic estrogen-alone products keep a boxed warning about endometrial cancer risk for women who still have a uterus. Source: FDA press announcement

None of this is medical advice, and it cannot be. Whether HRT fits your body is a decision for you and your doctor, weighing your symptoms, your age, your family history, and your preferences. If you were told no years ago, this is a good moment to ask again. If you are in perimenopause and unsure where you stand, that same conversation is worth having early.

What changed vs. what didn't

Here is the label change at a glance.

Sources: FDA, Contemporary OB/GYN

If anything on your own history list gives you pause, bring it to your doctor before making changes in either direction.

Where The Shift fits

Hormones address the hormonal side of the transition. They do not address everything, because peri/menopause is not only a hormone story. It is also a stress-response story: the system that governs tension, mental clarity, and whether you stay asleep at 3am.

The Shift is Project M's daily herbal protocol for peri/menopause, built on a 600-year-old Traditional Chinese Medicine (TCM) formula and designed to support the body's stress response during the transition. In Project M's 35-woman consumer research study, the 8 women on HRT scored notably lower on emotional dysregulation and bloating than non-HRT users. Their brain fog, can't-unwind tension, and sleep wakings were essentially unchanged. Source: Project M study results

That gap is why many women use both, and why Project M sees this label change as unambiguously good news. More safe options for women is the goal. If you want the full picture of how the two approaches differ and combine, see The Shift vs. HRT and taking The Shift with HRT. And as with HRT itself, loop in your doctor about everything you take.

Frequently asked questions

Did the FDA say HRT is completely safe?

No. The FDA removed a broad, outdated warning; it did not declare HRT risk-free. Labels will still describe risks, one boxed warning remains on systemic estrogen-alone products, and screening for personal risk factors is still part of prescribing. Source: FDA

Why was the old warning considered misleading?

Because it was built largely on the 2002 WHI trial, whose participants averaged 63 years old and used older formulations. Applying those findings to healthy women in their 40s and 50s overstated risk for the group most likely to benefit. Source: Harvard Health Publishing

I was told years ago I couldn't take HRT. Should I ask again?

It is reasonable to revisit the conversation, especially if the earlier "no" was based on general fear rather than your specific history. Some restrictions still apply, including prior breast cancer, blood clots, or stroke. Your doctor can walk through your individual picture.

If I start HRT, do I still need other support?

Possibly. In Project M's consumer research study, HRT users still reported brain fog, tension, and night wakings at levels similar to non-users. Many women pair HRT with stress-response support such as The Shift, with their doctor's knowledge. Source: Project M study results

Does this change affect vaginal estrogen too?

Yes. Low-dose vaginal estrogen also lost the boxed warning, a change The Menopause Society specifically endorsed because very little of it reaches the bloodstream. Source: The Menopause Society

The transition deserves a full toolkit. This label change just made the toolkit bigger.

Read next

• The Shift vs. HRT: how they differ and where they overlap
• Taking The Shift with HRT
• What is perimenopause?
• Why you wake at 3am: peri/menopause sleep disruption